Insider · CIK 0001602064
Robert Carey
Files at SGMOQ (SANGAMO THERAPEUTICS, INC), XAIR (Beyond Air, Inc.). First filing Mar 17, 2025, latest Mar 17, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XAIR: Beyond Air, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -4,500 | - | - | 0 | Nov 7, 2025 |
| Nov 3, 2025 | XAIR Beyond Air, Inc. | JOther Warrants to purchase Common Stockderivative | +512,821 | - | - | 512,821 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +4,500 | - | - | 4,500 | Nov 7, 2025 |
| Nov 3, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Warrants to purchase Common Stockderivative | -494,332 | - | - | 0 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -2,000 | - | - | 0 | Nov 7, 2025 |
| Nov 3, 2025 | XAIR Beyond Air, Inc. | AGrant or award Warrants to purchase Common Stockderivative | +494,332 | - | - | 494,332 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +2,000 | - | - | 2,000 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -1,500 | - | - | 0 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +1,500 | - | - | 1,500 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -1,250 | - | - | 0 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +1,250 | - | - | 1,250 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -1,250 | - | - | 0 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +1,250 | - | - | 1,250 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -50 | - | - | 0 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +50 | - | - | 50 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -1,250 | - | - | 0 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +1,250 | - | - | 1,250 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -10,000 | - | - | 0 | Nov 7, 2025 |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +10,000 | - | - | 10,000 | Nov 7, 2025 |
| Jun 12, 2025 | SGMOQ SANGAMO THERAPEUTICS, INC | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 99,600 | Jun 16, 2025 |
| Jun 12, 2025 | SGMOQ SANGAMO THERAPEUTICS, INC | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 16, 2025 |
| Mar 26, 2025 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Mar 28, 2025 |
| Mar 14, 2025 | XAIR Beyond Air, Inc. | POpen-market purchase Common Stock | +990,000 | $0.25 | $248k | 4,066,864 | Mar 17, 2025 |
| Mar 14, 2025 | XAIR Beyond Air, Inc. | POpen-market purchase Common Stock | +10,000 | $0.26 | $2,550 | 4,076,864 | Mar 17, 2025 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -90,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +90,000 | - | - | 90,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -40,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +40,000 | - | - | 40,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -30,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +30,000 | - | - | 30,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -25,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +25,000 | - | - | 25,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -25,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +25,000 | - | - | 25,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -1,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +1,000 | - | - | 1,000 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | DDisposition to issuer Stock Options (Right to buy)derivative | -25,000 | - | - | 0 | Nov 26, 2024 |
| Nov 22, 2024 | XAIR Beyond Air, Inc. | AGrant or award Stock Options (Right to buy)derivative | +25,000 | - | - | 25,000 | Nov 26, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.